Transgene

Transgene PP&E per Employee

The PP&E per Employee of Transgene (TNG.PA) as of Nov 2, 2026 is 89,893.08 EUR. In the previous year, PP&E per Employee was 77,446.54 EUR — a change of 16.07% (higher).

PP&E per Employee

89,893.08EUR

YoY

16.07%

Last updated:

PP&E per Employee of Transgene is 2024 89,893.08 EUR. PP&E per Employee of Transgene was 2023 77,446.54 EUR. It decreases by 16.07% higher compared to the previous year.

The Transgene PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2017
85,559.75 EUR
Jan 1, 2018
83,779.87 EUR
Jan 1, 2019
83,540.88 EUR
Jan 1, 2020
82,452.83 EUR
Jan 1, 2021
71,037.74 EUR
Jan 1, 2022
70,295.60 EUR
Jan 1, 2023
77,446.54 EUR
Jan 1, 2024
89,893.08 EUR
The Transgene PP&E per Employee history
YEARPP&E per EmployeeYoY
89,893.08EUR+16.07%
77,446.54EUR+10.17%
70,295.60EUR-1.04%
71,037.74EUR-13.84%
82,452.83EUR-1.30%
83,540.88EUR-0.29%
83,779.87EUR-2.08%
85,559.75EUR-6.69%
91,698.11EUR-11.95%
104,144.65EUR-29.96%
148,685.53EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

PP&E per Employee of Transgene is 89,893.08 EUR in 2024.

PP&E per Employee of Transgene changed from 77,446.54 EUR to 89,893.08 EUR, representing a 16.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Transgene since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Transgene

All Key Metrics — Transgene